Recursion Pharmaceuticals, Inc. RXRX Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s contract liabilities?
- Recursion Pharmaceuticals, Inc. (RXRX) reported contract liabilities of $114.72M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s contract liabilities changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s contract liabilities decreased by 11.5% year-over-year, from $129.61M to $114.72M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s contract liabilities?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s contract liabilities has grown at a 46.9% compound annual growth rate (CAGR), from $16.67M to $114.01M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.